Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease

Franco Locatelli, Daria Pagliara

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 8590% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications. Pediatr Blood Cancer 2012;59:372376. (c) 2012 Wiley Periodicals, Inc.
Lingua originaleEnglish
pagine (da-a)372-376
Numero di pagine5
RivistaPEDIATRIC BLOOD & CANCER
Volume59
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • sickle cell disease
  • mixed chimerism
  • cord blood transplantation

Fingerprint

Entra nei temi di ricerca di 'Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease'. Insieme formano una fingerprint unica.

Cita questo